Skip to content
Home/Companies/Biotech/ProTgen

ProTgen

Biotech·United States·Active·2yr hold
Entry
2024
Hold
2yr
Status
Active

Who owns ProTgen?

ProTgen is an American Biotech company, currently owned by Boehringer Ingelheim Venture Fund since 2024.

Hand-verified · updated 2026-07-03

Open JSON · CC-BY
Boehringer Ingelheim Venture Fund
Investor
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund · 2010 · Evergreen

Key facts

HQUnited States
SectorBiotech
StatusActive

More from Boehringer Ingelheim Venture Fund

Other portfolio companies in the same fund.

ICD Therapeutics
Exited 2019
BiotechGermany
to Boehringer Ingelheim
EvlaBio
Active
BiotechGermany· 2025
Refoxy Pharmaceuticals
Refoxy Pharmaceuticals
Active
BiotechGermany· 2024
SwitchKine
Active
BiotechSwitzerland· 2024
Synthetica Pioneering
Active
BiotechChina· 2024
Aurobac Therapeutics
Aurobac Therapeutics
Active
BiotechFrance· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns ProTgen?

ProTgen is currently owned by Boehringer Ingelheim Venture Fund, through Boehringer Ingelheim Venture Fund, since 2024.

When did Boehringer Ingelheim Venture Fund acquire ProTgen?

Boehringer Ingelheim Venture Fund acquired ProTgen in 2024.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue